<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387763</url>
  </required_header>
  <id_info>
    <org_study_id>daliah2011</org_study_id>
    <nct_id>NCT01387763</nct_id>
  </id_info>
  <brief_title>A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms</brief_title>
  <acronym>DALIAH</acronym>
  <official_title>Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Stauffer Larsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy and toxicity including quality of life of
      two types of low-dose interferon alpha compounds (PegIntron and Pegasys) with hydroxyurea
      (Hydrea), and to investigate the occurence of neutralizing antibodies against recombinant
      interferon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV),
      essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have
      many overlapping clinical features. The diseases are clonal stem cell disorders characterized
      by a chronic excess production of mainly mature myeloid cells. The excess production of
      clonal red cells (in PV), platelets (in PV, ET and PMF) and leukocytes (mainly PV and
      PMF)leads to a highly increased risk of thrombosis. Patients may also suffer from
      constitutional symptoms, pruritus and splenomegaly. An inherent feature of these diseases are
      the risk of ET and PV of transformation to myelofibrosis and a risk of both ET, PV and PMF of
      leukemic transformation.

      In 2005 major breakthrough in our understanding of the molecular pathophysiology was achieved
      with the identification of the JAK2 V617F mutation which is present in almost all patients
      with PV (98%) and about half of patients with ET and PMF. This somatic gain-of-function point
      mutation in the JAK2 tyrosine kinase leads to constitutive activation of the kinase. By this
      mechanism a clonal non-growth factor dependent myeloproliferation is established.

      Traditionally the excess platelet and white cell production in ET, PV and PMF has been
      treated with cytoreductive agents such as hydroxyurea and busulfan in order to normalize the
      blood counts and thereby reducing the risk of thrombosis. However, in younger patients there
      is a concern of the leukemogenic potential of these agents. In younger patients an
      alternative treatment option is recombinant pegylated interferon alpha (IFN-alpha), which has
      demonstrated high clinical efficacy and has no leukemogenic potential. Within recent years
      IFN-alpha has demonstrated a capacity of inducing deep molecular remission (evaluated by JAK2
      V617F qPCR) and normalisation of bone marrow morphology. These remissions have been sustained
      for up to 3 years after discontinuation of IFN-alpha therapy. Accordingly a perspective of
      changing the natural history of these disorders towards myelofibrosis and ultimately acute
      leukemia has emerged. However toxicity has been a major issue and drop-of rates have been
      reported consistently around 25 %.

      It is well known from other diseases (e.g multiple sclerosis and hepatitis) that some
      patients develop neutralizing antibodies against IFN-alpha. This issue is however only
      scarcely investigated in CMPN and has never been tested in a prospective design.

      The purpose of this study is to compare the efficacy (hematological and molecular) and
      toxicity profile of two different recombinant interferon alpha products, IFN-alpha2a and
      IFN-alpha2b in a prospective randomized design. In patients over the age of 60 there will be
      a third study arm with hydroxyurea.

      In order to decrease drop out rates and thereby increasing response rates patients will be
      started of at a low-dose of IFN-alpha. If patients fail to respond or looses their response
      and develops neutralizing antibodies against IFN-alpha therapy will be stopped. If patients
      have a sustained deep molecular response (below 1 % JAK2 V617F mutated alleles for 12 months)
      therapy will be stopped to asses the sustainability of the remission off therapy.Patients
      over the age of 75 and intolerant or resistant to hydroxyurea will be offered rescue
      treatment with orally busulfan (Myleran). As an important part of the study quality of life
      will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>molecular response (changes from baseline)</measure>
    <time_frame>18, 36 and 60 months</time_frame>
    <description>Molecular responses (JAK V617F allele burden) are assessed by qPCR according to the ELN guidelines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity (discontinuation of therapy due to intolerability)</measure>
    <time_frame>18 months</time_frame>
    <description>The proportion of patients treated with PegIntron, Pegasys and Hydrea who need to discontinue therapy due to intolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (changes from baseline)</measure>
    <time_frame>4, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Quality of life will be evaluated according to EORTC QLQ C-30 and MPN-SAF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological response (changes from baseline)</measure>
    <time_frame>36 and 60 months</time_frame>
    <description>A bone marrow sample will be evaluated in order to detect and grade changes in bone marrow morphology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained molecular response (changes from level at time of discontinuation of therapy)</measure>
    <time_frame>12, 24 and 36 months</time_frame>
    <description>investigation of the sustainability of an obtained molecular remission (&lt;
1% JAK2V617F mutated alleles) after discontinuation of interferon- alpha( Pegasys, PegIntron, Multiferon) or Hydrea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies against PegIntron and Pegasys</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients treated with Peintron and Pegasys who have developed neutralizing antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematological response</measure>
    <time_frame>12 months</time_frame>
    <description>Hematological response will be evaluated according to the ELN guidelines.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Primary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>PegIntron &lt;= 60 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients &lt;= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys &lt;= 60 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients &lt;= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PegIntron &gt; 60 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients &lt; 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys &gt; 60 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients &gt; 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxyurea &gt; 60 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsule Hydrea 500-2000 mg orally QD or BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIntron</intervention_name>
    <description>PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.</description>
    <arm_group_label>PegIntron &lt;= 60 years</arm_group_label>
    <other_name>Pegylated interferon alpha 2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly</description>
    <arm_group_label>Pegasys &lt;= 60 years</arm_group_label>
    <other_name>Pegylated interferon alpha 2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIntron</intervention_name>
    <description>PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.</description>
    <arm_group_label>PegIntron &gt; 60 years</arm_group_label>
    <other_name>Pegylated interferon alpha 2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly</description>
    <arm_group_label>Pegasys &gt; 60 years</arm_group_label>
    <other_name>Pegylated interferon alpha 2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrea</intervention_name>
    <description>Capsule Hydrea 500-2000 mg orally QD or BID</description>
    <arm_group_label>Hydroxyurea &gt; 60 years</arm_group_label>
    <other_name>hydroxyurea</other_name>
    <other_name>hydroxycarbamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt; 18 years of age

          -  Newly diagnosed, or previously diagnosed untreated patients with ET, PV or PMF
             including prefibrotic myelofibrosis according to the WHO classification

          -  Active disease defined by one of the following criteria:

          -  need for phlebotomy

          -  leukocytosis &gt; 10 mia/l

          -  thrombocytosis &gt; 400 mia/l

          -  constitutional symptoms (fatigue, weight loss, night sweats or fewer &gt; 38 degrees
             celsius)

          -  Pruritus

          -  splenomegaly causing symptoms

          -  previous thrombosis

        Exclusion Criteria:

          -  Fertile women without a negative pregnancy test

          -  Other malignant disease within last 5 years

          -  ECOG performance score &gt;/= 3

          -  Creatinine &gt; 2x ULN

          -  Bilirubin &gt; 1.5x ULN

          -  ALAT &gt; 3x ULN

          -  Previous psychiatric disorder (depression)

          -  active autoimmune disease

          -  Uncontrolled thyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas S Larsen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Hematology, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Hematology, Aalborg hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Hematology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Hematology, Esbjerg Hospital</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Hematology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Hematology, Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Hematology, Rigshospitalet</name>
      <address>
        <city>KÃ¸benhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of hematology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Hematology, Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Stauffer Larsen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

